Publications by B BIENVENU

Publications by authors named "B BIENVENU"

Rev Med Interne

January 2025

The purpose of this project was to update the 2016 recommendations regarding the management of immunosuppressants or biologics in patients with giant cell arteritis (GCA).
A task force of 18 physicians developed 26 validated recommendations after thorough discussion and a >85% consensus process.
Key recommendations include using subcutaneous tocilizumab (TCZ) as a first-line treatment when glucocorticoid-sparing is needed, initiating TCZ at diagnosis for patients with specific high-risk conditions, and considering TCZ or methotrexate if glucocorticoid discontinuation is not feasible after 12 months.

Rev Med Interne

January 2025

Giant cell arteritis (GCA) primarily affects women over 50, causing symptoms like headaches and jaw pain, and can lead to severe complications like vision loss due to eye involvement.
Diagnosis relies on advanced imaging techniques such as FDG-PET and CT scans, while the temporal artery biopsy is considered the gold standard.
Urgent treatment with high doses of corticosteroids is critical to prevent vision loss, and long-term management is necessary to monitor for recurrence and potential cardiovascular issues.

Rev Med Interne

October 2024

* It typically affects Caucasians equally across genders and can also be associated with other autoimmune diseases like polyarteritis nodosa.
* While ocular symptoms often have a good prognosis with potential recovery of vision, cochleo-vestibular issues can lead to serious and irreversible hearing loss, and treatment options are not well-established due to the condition's rarity.

Lancet Microbe

November 2024

* This study analyzed cases of C bantiana infections in France and its territories, involving patients who were diagnosed through a comprehensive surveillance program, focusing on survival rates and the presence of central nervous system (CNS) involvement.
* Out of 23 patients identified from 2002 to 2022, 65% had CNS involvement, with a notable increase in cases reported in 2022, indicating a possible correlation with environmental factors like rising temperatures.

J Fr Ophtalmol

January 2025

This study explores how Graves' orbitopathy (GO) is managed across 26 medical centers in France, focusing on the structure and availability of treatment services.
Researchers contacted 28 centers to gather data through a questionnaire about multidisciplinary meetings, dedicated services, and treatment methods.
The findings revealed that while a majority have dedicated services and utilize first-line treatments like intravenous corticosteroids, there’s significant variability in practices, highlighting the need for standardization and improving accessibility to new treatments like tocilizumab and teprotumumab.